<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomed Res Int</journal-id><journal-id journal-id-type="iso-abbrev">Biomed Res Int</journal-id><journal-id journal-id-type="publisher-id">BMRI</journal-id><journal-title-group><journal-title>BioMed Research International</journal-title></journal-title-group><issn pub-type="ppub">2314-6133</issn><issn pub-type="epub">2314-6141</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4066711</article-id><article-id pub-id-type="doi">10.1155/2014/364625</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Potential Mitochondrial Isocitrate Dehydrogenase R140Q Mutant Inhibitor from Traditional Chinese Medicine against Cancers</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Wen-Yuan</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Kuan-Chung</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Hsin-Yi</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Calvin Yu-Chian</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Biomedical Informatics, Asia University, Taichung 41354, Taiwan</aff><aff id="I2"><sup>2</sup>School of Medicine, College of Medicine, China Medical University, Taichung 40402, Taiwan</aff><aff id="I3"><sup>3</sup>Department of Neurosurgery, China Medical University Hospital, Taichung 40447, Taiwan</aff><aff id="I4"><sup>4</sup>School of Pharmacy, China Medical University, Taichung 40402, Taiwan</aff><aff id="I5"><sup>5</sup>Research Center for Chinese Medicine &amp; Acupuncture, China Medical University, Taichung 40402, Taiwan</aff><author-notes><corresp id="cor1">*Calvin Yu-Chian Chen: <email>ycc929@MIT.edu</email></corresp><fn fn-type="other"><p>Academic Editor: Chung Y. Hsu</p></fn></author-notes><pub-date pub-type="ppub"><year>2014</year></pub-date><pub-date pub-type="epub"><day>5</day><month>6</month><year>2014</year></pub-date><volume>2014</volume><elocation-id>364625</elocation-id><history><date date-type="received"><day>16</day><month>2</month><year>2014</year></date><date date-type="rev-recd"><day>4</day><month>3</month><year>2014</year></date><date date-type="accepted"><day>4</day><month>3</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#169; 2014 Wen-Yuan Lee et al.</copyright-statement><copyright-year>2014</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>A recent research of cancer has indicated that the mutant of isocitrate dehydrogenase 1 and 2 (<italic>IDH1</italic> and <italic>2</italic>) genes will induce various cancers, including chondrosarcoma, cholangiocarcinomas, and acute myelogenous leukemia due to the effect of point mutations in the active-site arginine residues of isocitrate dehydrogenase (IDH), such as IDH1/R132, IDH2/R140, and IDH2/R172. As the inhibition for those tumor-associated mutant IDH proteins may induce differentiation of those cancer cells, these tumor-associated mutant IDH proteins can be treated as a drug target proteins for a differentiation therapy against cancers. In this study, we aim to identify the potent TCM compounds from the TCM Database@Taiwan as lead compounds of IDH2 R140Q mutant inhibitor. Comparing to the IDH2 R140Q mutant protein inhibitor, AGI-6780, the top two TCM compounds, precatorine and abrine, have higher binding affinities with target protein in docking simulation. After MD simulation, the top two TCM compounds remain as the same docking poses under dynamic conditions. In addition, precatorine is extracted from <italic>Abrus precatorius</italic> L., which represents the cytotoxic and proapoptotic effects for breast cancer and several tumor lines. Hence, we propose the TCM compounds, precatorine and abrine, as potential candidates as lead compounds for further study in drug development process with the IDH2 R140Q mutant protein against cancer.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Nowadays, in accordance with more and more mechanisms of diseases being identified [<xref rid="B1" ref-type="bibr">1</xref>&#8211;<xref rid="B6" ref-type="bibr">6</xref>], there are increasing numbers of potential target proteins against each disease, which are useful for drug design [<xref rid="B7" ref-type="bibr">7</xref>&#8211;<xref rid="B11" ref-type="bibr">11</xref>]. The recent research of cancer has indicated that the mutant of isocitrate dehydrogenase 1 and 2 (<italic>IDH1</italic> and<italic> 2</italic>) genes will induce various cancers [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>]. Somatic mutations in the isocitrate dehydrogenase 1 and 2 genes affecting point mutations in the active-site arginine residues of isocitrate dehydrogenase (IDH), such as IDH1/R132, IDH2/R140, and IDH2/R172, occur frequently in many cancers, including chondrosarcoma, cholangiocarcinomas, and acute myelogenous leukemia [<xref rid="B14" ref-type="bibr">14</xref>&#8211;<xref rid="B22" ref-type="bibr">22</xref>]. The inhibition for those tumor-associated mutant IDH proteins may induce differentiation of those cancer cells. The tumor-associated mutant IDH proteins can be treated as a drug target proteins for a differentiation therapy against cancers [<xref rid="B23" ref-type="bibr">23</xref>].</p><p>Nowadays, the computer-aided drug design has been widely used in drug designing [<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>]. Increasing numbers of compounds extracted from traditional Chinese medicine (TCM) have been indicated as potential lead compounds against cancers [<xref rid="B26" ref-type="bibr">26</xref>&#8211;<xref rid="B28" ref-type="bibr">28</xref>], inflammation [<xref rid="B29" ref-type="bibr">29</xref>], influenza [<xref rid="B30" ref-type="bibr">30</xref>], viral infection [<xref rid="B31" ref-type="bibr">31</xref>], metabolic syndrome [<xref rid="B32" ref-type="bibr">32</xref>], diabetes [<xref rid="B33" ref-type="bibr">33</xref>], stroke [<xref rid="B34" ref-type="bibr">34</xref>&#8211;<xref rid="B36" ref-type="bibr">36</xref>], and many other diseases [<xref rid="B37" ref-type="bibr">37</xref>&#8211;<xref rid="B41" ref-type="bibr">41</xref>]. A recent research of mutant IDH2 protein shows a compound, AGI-6780, which can inhibit the tumor-associated mutant IDH2/R140Q [<xref rid="B42" ref-type="bibr">42</xref>]. For drug development of TCM compounds, we aim to identify the potent TCM compounds from the TCM Database@Taiwan [<xref rid="B43" ref-type="bibr">43</xref>] as lead compounds of IDH2 R140Q mutant inhibitor. As structural disordered disposition in the protein may induce the side effect and reduce the occupancy for ligand to bind with target protein [<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>], PONDR-Fit protocol was performed to predict the disordered disposition in IDH2 protein before virtual screening. After virtual screening, the MD simulation was performed to validate the stability of interactions between IDH2 R140Q mutant proteins and each ligand.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><sec id="sec2.1"><title>2.1. Data Collection</title><p>The X-ray crystallography structure of the human mitochondrial isocitrate dehydrogenase (IDH2) R140Q mutant was downloaded from RCSB Protein Data Bank with PDB ID: 4JA8 [<xref rid="B42" ref-type="bibr">42</xref>]. To predict the disordered amino acids, PONDR-Fit [<xref rid="B46" ref-type="bibr">46</xref>] protocol was employed with the sequence of IDH2 protein from Swiss-Prot (UniProtKB: P48735). In preparation section, X-ray crystallography structure of IDH2 R140Q mutant protein was protonated with Chemistry at HARvard Macromolecular Mechanics (CHARMM) force field [<xref rid="B47" ref-type="bibr">47</xref>] and removed crystal water by Prepare Protein module in Discovery Studio 2.5 (DS2.5). The final structure of TCM compounds from TCM Database@Taiwan [<xref rid="B43" ref-type="bibr">43</xref>] was protonated and filtered by Lipinski's Rule of Five [<xref rid="B48" ref-type="bibr">48</xref>] using Prepare Ligand module in DS2.5. The binding site for virtual screening was defined by the volume of the cocrystallized IDH2 R140Q mutant inhibitor, AGI-6780.</p></sec><sec id="sec2.2"><title>2.2. Docking Simulation</title><p>The TCM compounds were docking into the binding site using a shape filter and Monte-Carlo ligand conformation generation by LigandFit protocol [<xref rid="B49" ref-type="bibr">49</xref>] in DS 2.5. The docking poses were optionally minimized with CHARMM force field [<xref rid="B47" ref-type="bibr">47</xref>] and filtered the similar poses by the clustering algorithm. Each docking pose was evaluated by the following Dock Score energy function:<list list-type="simple"><list-item><label>&#8201;</label><p>Dock Score = &#8722; (ligand/receptor interaction energy + ligand internal energy).</p></list-item></list>
</p></sec><sec id="sec2.3"><title>2.3. Molecular Dynamics (MD) Simulation</title><p>The molecular dynamics (MD) simulation utilizing Gromacs 4.5.5 [<xref rid="B50" ref-type="bibr">50</xref>] was employed using classical molecular dynamics theory to simulate each protein-ligand complex under dynamic conditions. In preparation section, the IDH2 R140Q mutant proteins were prepared by pdb2gmx protocol of Gromacs to provide topology and parameters with charmm27 force field, and each ligand was prepared by SwissParam program [<xref rid="B51" ref-type="bibr">51</xref>]. A cubic box solvated using TIP3P water model was defined based upon the edge approx. 1.2&#8201;nm from the protein complexes periphery. In the minimization section, the steepest descent [<xref rid="B52" ref-type="bibr">52</xref>] minimization was employed with a maximum of 5,000 steps to remove bad van der Waals contacts. Gromacs program creates a neutral system using 0.145&#8201;M NaCl model, followed by another steepest descent minimization with a maximum of 5,000 steps to remove bad van der Waals contacts. In the equilibration section, Gromacs program performs a position-restrained molecular dynamics with the linear constraint algorithm for all bonds, NVT equilibration, Berendsen weak thermal coupling method, and particle mesh Ewald method. In the production section, Gromacs program performs a total of 5000&#8201;ps production simulation with time step in unit of 2&#8201;fs under NPT ensembles and particle mesh Ewald (PME) option. A series of protocols in Gromacs program was utilized to analyze the 5000&#8201;ps MD trajectories. The CAVER 3.0 [<xref rid="B53" ref-type="bibr">53</xref>] was employed to analyze the presumably pathways for small molecule under dynamics conditions.</p></sec></sec><sec id="sec3"><title>3. Results and Discussion</title><sec id="sec3.1"><title>3.1. Disordered Protein Prediction</title><p>The sequence of IDH2 protein from Swiss-Prot (UniProtKB: P48735) was employed to predict the disordered disposition by PONDR-Fit protocol. As illustrated in <xref ref-type="fig" rid="fig1">Figure 1</xref>, the key residues in the binding domain have no disordered disposition, which express a stable binding domain in protein folding. It indicates that the binding domain in the crystallography structure of target protein will be suitable for docking simulation as the residues in the binding domain have no significant variation.</p></sec><sec id="sec3.2"><title>3.2. Docking Simulation</title><p>To validate the accuracy of LigandFit protocol, we redock the cocrystallized IDH2 R140Q mutant inhibitor, AGI-6780, into the binding site of IDH2 R140Q mutant proteins. Root-mean-square deviation (RMSD) value between crystallized structure and docking pose of AGI-6780 is 0.3683&#8201;&#197; (<xref ref-type="fig" rid="fig2">Figure 2</xref>), which indicates that the docking simulation by LigandFit protocol is suitable for virtual screening with IDH2 R140Q mutant proteins. After virtual screening, the chemical scaffolds of AGI-6780 and top two TCM compounds are displayed in <xref ref-type="fig" rid="fig3">Figure 3</xref> with Dock Score and sources. Precatorine is extracted from<italic> Abrus precatorius</italic> L., and abrine is extracted from<italic> Abrus fruticuIosus Wall. ex Wight et Arn.</italic> The compounds extracted from<italic> Abrus precatorius</italic> L. had been indicated to have the antimicrobial activity [<xref rid="B54" ref-type="bibr">54</xref>], antibacterial activity [<xref rid="B55" ref-type="bibr">55</xref>], cytotoxic and proapoptotic effects for breast cancer [<xref rid="B56" ref-type="bibr">56</xref>], and several tumor lines [<xref rid="B57" ref-type="bibr">57</xref>]. <xref ref-type="fig" rid="fig4"> Figure 4</xref> illustrated the docking poses of IDH2 R140Q mutant protein complexes with AGI-6780 and top two TCM compounds, respectively. The IDH2 R140Q mutant protein inhibitor, AGI-6780, has hydrogen bonds (H-bonds) with residues Gln316 in both chains of IDH2 R140Q mutant protein and a <italic>&#960;</italic> interaction with residue Ile319 in chain B of IDH2 R140Q mutant protein. For the top TCM candidates, they also have H-bonds with residues Gln316 in both chains of IDH2 R140Q mutant protein as AGI-6780. For abrine, it has a <italic>&#960;</italic> interaction with residue Ile319 in chain A of IDH2 R140Q mutant protein.</p></sec><sec id="sec3.3"><title>3.3. Molecular Dynamics Simulation</title><p>For the docking simulation performed by LigandFit protocol, the receptor is a rigid body of IDH2 R140Q mutant proteins. The conformation of the IDH2 R140Q mutant protein may modify under dynamic conditions. We employed the MD simulation to validate the stability of interactions between IDH2 R140Q mutant proteins and each ligand. RMSDs illustrated the atomic fluctuations during MD simulation. <xref ref-type="fig" rid="fig5"> Figure 5</xref> displays the atomic fluctuations of IDH2 R140Q mutant proteins in apo form and complexes with AGI-6780, precatorine, and abrine and the atomic fluctuations of each compound during 5000&#8201;ps MD simulation. It shows that IDH2 R140Q mutant proteins tend to be stable after first 100&#8201;ps MD simulation, but the ligands except precatorine are fluctuate during MD simulation. To consider the variation radii of gyration for protein and total energy over 5000&#8201;ps MD simulation in <xref ref-type="fig" rid="fig6">Figure 6</xref>, it indicates that the radii of gyration for IDH2 R140Q mutant proteins in apo form were decreased after 4500&#8201;ps MD simulation, but the radii of gyration for complexes of IDH2 R140Q mutant proteins with AGI-6780, precatorine, and abrine were more stabilized. In addition, there is no significant change for the total energies of each IDH2 R140Q mutant protein complex during MD simulation in <xref ref-type="fig" rid="fig7">Figure 7</xref>. The variation of solvent accessible surface area over 5000&#8201;ps MD simulation in <xref ref-type="fig" rid="fig8">Figure 8</xref> indicates that docking the ligands, AGI-6780, precatorine, and abrine, would not affect the solvent accessible surface of IDH2 R140Q mutant protein under dynamic conditions. The mean square displacement (MSD) for each protein and ligand in IDH2 R140Q mutant proteins and protein complexes with AGI-6780, precatorine, and abrine over 5000&#8201;ps of MD simulation is displayed in <xref ref-type="fig" rid="fig9">Figure 9</xref>. Root-mean-square fluctuation (RMSF) for each residue over 5000&#8201;ps MD simulation is displayed in <xref ref-type="fig" rid="fig10">Figure 10</xref>. They indicate that IDH2 R140Q mutant protein docking with precatorine and abrine causes similar diffusion constant and flexibility for IDH2 R140Q mutant proteins as AGI-6780.</p><p>After MD simulation, we identify the representative structures of IDH2 R140Q mutant proteins in apo form and in each complex using the RMSD values and graphical depiction of the clusters analysis with a RMSD cutoff of 0.105&#8201;nm in <xref ref-type="fig" rid="fig11">Figure 11</xref>. The docking poses of the representative structures for complexes of IDH2 R140Q mutant proteins with AGI-6780, precatorine, and abrine are illustrated in <xref ref-type="fig" rid="fig12">Figure 12</xref>. To compare with the result in docking simulation, the IDH2 R140Q mutant protein inhibitor, AGI-6780, has stable hydrogen bonds (H-bonds) with residues Gln316 in both chains of IDH2 R140Q mutant protein and forms a <italic>&#960;</italic> interaction with residue Val315 in chain B of IDH2 R140Q mutant protein. For TCM candidates, they have similar docking poses as docking simulation, which has stable H-bonds with residues Gln316. The H-bond occupancy for key residues in complexes of IDH2 R140Q mutant protein with AGI-6780 and top TCM compounds overall 5000&#8201;ps of molecular dynamics simulation in <xref ref-type="table" rid="tab1">Table 1</xref> displayed the stability of H-bonds. Analysis of transport pathways for each IDH2 R140Q mutant protein complex illustrated in <xref ref-type="fig" rid="fig13">Figure 13</xref> shows the presumably pathways for small molecule. They indicate that IDH2 R140Q mutant protein docking with precatorine and abrine has similar effects of protein conformation as AGI-6780.</p></sec></sec><sec id="sec4"><title>4. Conclusion</title><p>This study aims to investigate the potent lead TCM candidates for IDH2 R140Q mutant protein inhibitors against cancers. Compared to the IDH2 R140Q mutant protein inhibitor, AGI-6780, the top two TCM compounds, precatorine and abrine, have higher binding affinities with target protein in docking simulation. Both of them has H-bonds with residues Gln316 in both chains of IDH2 R140Q mutant protein as AGI-6780. After MD simulation, the top two TCM compounds remain as the same docking poses under dynamic conditions. In addition, precatorine is extracted from<italic> Abrus precatorius</italic> L., which has been indicated to have the cytotoxic and proapoptotic effects for breast cancer and several tumor lines. Hence, we propose the TCM compounds, precatorine and abrine, as potential candidates as lead compounds for further study in drug development process with the IDH2 R140Q mutant protein against cancer.</p></sec></body><back><ack><title>Acknowledgments</title><p>The research was supported by Grants from the National Science Council of Taiwan (NSC102-2325-B039-001, and NSC102-2221-E-468-027-), Asia University (ASIA100-CMU-2, ASIA101-CMU-2, and 102-ASIA-07), and China Medical University Hospital (DMR-103-058, DMR-103-001, and DMR-103-096). This study is also supported in part by Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH102-TD-B-111-004) and Taiwan Department of Health Cancer Research Center of Excellence (MOHW103-TD-B-111-03), and CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan.</p></ack><sec sec-type="conflict"><title>Conflict of Interests</title><p>The authors declare that there is no conflict of interests regarding the publication of this paper.</p></sec><sec><title>Authors' Contribution</title><p>Wen-Yuan Lee, Kuan-Chung Chen, and Hsin-Yi Chen contributed equally to this paper.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>I-C</given-names></name><name><surname>Lin</surname><given-names>W-D</given-names></name><name><surname>Wang</surname><given-names>C-H</given-names></name><etal/></person-group><article-title>Association analysis between Tourette&#8217;s syndrome and two dopamine genes (DAT1, DBH) in Taiwanese children</article-title><source><italic>BioMedicine</italic></source><year>2013</year><volume>3</volume><issue>2</issue><fpage>88</fpage><lpage>91</lpage><pub-id pub-id-type="other">2-s2.0-84876081328</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Hung</surname><given-names>W-C</given-names></name><name><surname>Takano</surname><given-names>T</given-names></name><name><surname>Nishiyama</surname><given-names>A</given-names></name></person-group><article-title>Genetic nature and virulence of community-associated methicillin-resistant Staphylococcus aureus</article-title><source><italic>BioMedicine</italic></source><year>2013</year><volume>3</volume><issue>1</issue><fpage>2</fpage><lpage>18</lpage><pub-id pub-id-type="other">2-s2.0-84875259470</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><etal/></person-group><article-title>PKM2 regulates chromosome segregation and mitosis progression of tumor cells</article-title><source><italic>Molecular Cell</italic></source><year>2014</year><volume>53</volume><issue>1</issue><fpage>75</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">24316223</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>Y-M</given-names></name><name><surname>Velmurugan</surname><given-names>BK</given-names></name><name><surname>Kuo</surname><given-names>W-W</given-names></name><etal/></person-group><article-title>Inhibitory effect of alpinate Oxyphyllae fructus extracts on Ang II-induced cardiac pathological remodeling-related pathways in H9c2 cardiomyoblast cells</article-title><source><italic>BioMedicine</italic></source><year>2013</year><volume>3</volume><issue>4</issue><fpage>148</fpage><lpage>152</lpage><pub-id pub-id-type="other">2-s2.0-84878732300</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>YM</given-names></name><name><surname>Wong</surname><given-names>KL</given-names></name><name><surname>Chen</surname><given-names>SW</given-names></name><etal/></person-group><article-title>Down-regulation of voltage-gated Ca<sup>2+</sup> channels in Ca<sup>2+</sup> store-depleted rat insulinoma RINm5F cells</article-title><source><italic>BioMedicine</italic></source><year>2013</year><volume>3</volume><issue>3</issue><fpage>130</fpage><lpage>139</lpage><pub-id pub-id-type="other">2-s2.0-84881370670</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahamuni</surname><given-names>SP</given-names></name><name><surname>Khose</surname><given-names>RD</given-names></name><name><surname>Menaa</surname><given-names>F</given-names></name><name><surname>Badole</surname><given-names>SL</given-names></name></person-group><article-title>Therapeutic approaches to drug targets in hyperlipidemia</article-title><source><italic>BioMedicine</italic></source><year>2012</year><volume>2</volume><issue>4</issue><fpage>137</fpage><lpage>146</lpage><pub-id pub-id-type="other">2-s2.0-84871609281</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leissring</surname><given-names>MA</given-names></name><name><surname>Malito</surname><given-names>E</given-names></name><name><surname>Hedouin</surname><given-names>S</given-names></name><etal/></person-group><article-title>Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin</article-title><source><italic>PLoS ONE</italic></source><year>2010</year><volume>5</volume><issue>5</issue><pub-id pub-id-type="other">2-s2.0-77956274306</pub-id><pub-id pub-id-type="publisher-id">e10504</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>M-C</given-names></name><name><surname>Tsai</surname><given-names>S-Y</given-names></name><name><surname>Wang</surname><given-names>F-Y</given-names></name><name><surname>Liu</surname><given-names>F-H</given-names></name><name><surname>Syu</surname><given-names>J-N</given-names></name><name><surname>Tang</surname><given-names>F-Y</given-names></name></person-group><article-title>Leptin induces cell invasion and the upregulation of matrilysin in human colon cancer cells</article-title><source><italic>BioMedicine</italic></source><year>2013</year><volume>3</volume><issue>4</issue><fpage>174</fpage><lpage>180</lpage></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssens</surname><given-names>V</given-names></name><name><surname>Goris</surname><given-names>J</given-names></name></person-group><article-title>Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling</article-title><source><italic>Biochemical Journal</italic></source><year>2001</year><volume>353</volume><issue>3</issue><fpage>417</fpage><lpage>439</lpage><pub-id pub-id-type="other">2-s2.0-0035252894</pub-id><pub-id pub-id-type="pmid">11171037</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>K-P</given-names></name></person-group><article-title>Inflammation in psychopathology of depression: clinical, biological, and therapeutic implications</article-title><source><italic>BioMedicine</italic></source><year>2012</year><volume>2</volume><issue>2</issue><fpage>68</fpage><lpage>74</lpage><pub-id pub-id-type="other">2-s2.0-84862764317</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jao</surname><given-names>C-L</given-names></name><name><surname>Huang</surname><given-names>S-L</given-names></name><name><surname>Hsu</surname><given-names>K-C</given-names></name></person-group><article-title>Angiotensin I-converting enzyme inhibitory peptides: inhibition mode, bioavailability, and antihypertensive effects</article-title><source><italic>BioMedicine</italic></source><year>2012</year><volume>2</volume><issue>4</issue><fpage>130</fpage><lpage>136</lpage><pub-id pub-id-type="other">2-s2.0-84871621268</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lokody</surname><given-names>I</given-names></name></person-group><article-title>Metabolism: IDH2 drives cancer in vivo</article-title><source><italic>Nature Reviews Cancer</italic></source><year>2013</year><volume>13</volume><issue>11</issue><fpage>756</fpage><lpage>757</lpage></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>BR</given-names></name><name><surname>Tangri</surname><given-names>R</given-names></name><name><surname>Ahmad</surname><given-names>F</given-names></name><name><surname>Roy</surname><given-names>A</given-names></name><name><surname>Patole</surname><given-names>K</given-names></name></person-group><article-title>Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patients</article-title><source><italic>Asian Pacific Journal of Cancer Prevention</italic></source><year>2013</year><volume>14</volume><issue>12</issue><fpage>7261</fpage><lpage>7264</lpage><pub-id pub-id-type="pmid">24460285</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yen</surname><given-names>KE</given-names></name><name><surname>Bittinger</surname><given-names>MA</given-names></name><name><surname>Su</surname><given-names>SM</given-names></name><name><surname>Fantin</surname><given-names>VR</given-names></name></person-group><article-title>Cancer-associated IDH mutations: biomarker and therapeutic opportunities</article-title><source><italic>Oncogene</italic></source><year>2010</year><volume>29</volume><issue>49</issue><fpage>6409</fpage><lpage>6417</lpage><pub-id pub-id-type="other">2-s2.0-78649990315</pub-id><pub-id pub-id-type="pmid">20972461</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Venneti</surname><given-names>S</given-names></name><name><surname>Akalin</surname><given-names>A</given-names></name><etal/></person-group><article-title>Induction of sarcomas by mutant IDH2</article-title><source><italic>Genes &amp; Development</italic></source><year>2013</year><volume>27</volume><issue>18</issue><fpage>1986</fpage><lpage>1998</lpage><pub-id pub-id-type="pmid">24065766</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition</article-title><source><italic>Genes &amp; Development</italic></source><year>2013</year><volume>27</volume><issue>18</issue><fpage>1974</fpage><lpage>1985</lpage><pub-id pub-id-type="pmid">24065765</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grassian</surname><given-names>AR</given-names></name><name><surname>Pagliarini</surname><given-names>R</given-names></name><name><surname>Chiang</surname><given-names>DY</given-names></name></person-group><article-title>Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma</article-title><source><italic>Current Opinion in Gastroenterology</italic></source><year>2014</year><volume>30</volume><issue>3</issue><fpage>295</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">24569570</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JB</given-names></name><name><surname>Dong</surname><given-names>DF</given-names></name><name><surname>Wang</surname><given-names>MD</given-names></name><name><surname>Gao</surname><given-names>K</given-names></name></person-group><article-title>IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo</article-title><source><italic>Asian Pacific Journal of Cancer Prevention</italic></source><year>2014</year><volume>15</volume><issue>1</issue><fpage>427</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">24528069</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JB</given-names></name><name><surname>Dong</surname><given-names>DF</given-names></name><name><surname>Gao</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>MD</given-names></name></person-group><article-title>Mechanisms underlying the biological changes induced by isocitrate dehydrogenase-1 mutation in glioma cells</article-title><source><italic>Oncology Letters</italic></source><year>2014</year><volume>7</volume><issue>3</issue><fpage>651</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">24520288</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kats</surname><given-names>LM</given-names></name><name><surname>Reschke</surname><given-names>M</given-names></name><name><surname>Taulli</surname><given-names>R</given-names></name><etal/></person-group><article-title>Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance</article-title><source><italic>Cell Stem Cell</italic></source><year>2014</year><volume>14</volume><issue>3</issue><fpage>329</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">24440599</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mylonas</surname><given-names>E</given-names></name><name><surname>Janin</surname><given-names>M</given-names></name><name><surname>Bawa</surname><given-names>O</given-names></name><etal/></person-group><article-title>Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice</article-title><source><italic>Leukemia</italic></source><year>2014</year></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabit</surname><given-names>H</given-names></name><name><surname>Nakada</surname><given-names>M</given-names></name><name><surname>Furuta</surname><given-names>T</given-names></name><etal/></person-group><article-title>Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence</article-title><source><italic>Brain Tumor Pathology</italic></source><year>2014</year></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bobrovnikova-Marjon</surname><given-names>E</given-names></name><name><surname>Hurov</surname><given-names>JB</given-names></name></person-group><article-title>Targeting metabolic changes in cancer: novel therapeutic approaches</article-title><source><italic>Annual Review of Medicine</italic></source><year>2014</year><volume>65</volume><fpage>157</fpage><lpage>170</lpage></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CY-C</given-names></name></person-group><article-title>A novel integrated framework and improved methodology of computer-aided drug design</article-title><source><italic>Current Topics in Medicinal Chemistry</italic></source><year>2013</year><volume>13</volume><issue>9</issue><fpage>965</fpage><lpage>988</lpage><pub-id pub-id-type="other">2-s2.0-84878775187</pub-id><pub-id pub-id-type="pmid">23651478</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H-J</given-names></name><name><surname>Yu</surname><given-names>HW</given-names></name><name><surname>Chen</surname><given-names>C-Y</given-names></name><etal/></person-group><article-title>Current developments of computer-aided drug design</article-title><source><italic>Journal of the Taiwan Institute of Chemical Engineers</italic></source><year>2010</year><volume>41</volume><issue>6</issue><fpage>623</fpage><lpage>635</lpage><pub-id pub-id-type="other">2-s2.0-78649451630</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C-Y</given-names></name><name><surname>Chen</surname><given-names>CY-C</given-names></name></person-group><article-title>Insights into designing the dual-targeted HER2/HSP90 inhibitors</article-title><source><italic>Journal of Molecular Graphics and Modelling</italic></source><year>2010</year><volume>29</volume><issue>1</issue><fpage>21</fpage><lpage>31</lpage><pub-id pub-id-type="other">2-s2.0-77955772552</pub-id><pub-id pub-id-type="pmid">20471294</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>S-C</given-names></name><name><surname>Chang</surname><given-names>S-S</given-names></name><name><surname>Chen</surname><given-names>H-Y</given-names></name><name><surname>Chen</surname><given-names>CY-C</given-names></name></person-group><article-title>Identification of potent EGFR inhibitors from TCM Database@Taiwan</article-title><source><italic>PLoS Computational Biology</italic></source><year>2011</year><volume>7</volume><issue>10</issue><pub-id pub-id-type="other">2-s2.0-80055077153</pub-id><pub-id pub-id-type="publisher-id">e1002189</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsou</surname><given-names>Y-A</given-names></name><name><surname>Chen</surname><given-names>K-C</given-names></name><name><surname>Lin</surname><given-names>H-C</given-names></name><name><surname>Chang</surname><given-names>S-S</given-names></name><name><surname>Chen</surname><given-names>CY-C</given-names></name></person-group><article-title>Uroporphyrinogen decarboxylase as a potential target for specific components of traditional Chinese medicine: a virtual screening and molecular dynamics study</article-title><source><italic>PLoS ONE</italic></source><year>2012</year><volume>7</volume><issue>11</issue><pub-id pub-id-type="other">2-s2.0-84870550823</pub-id><pub-id pub-id-type="publisher-id">e50087</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>K-C</given-names></name><name><surname>Sun</surname><given-names>M-F</given-names></name><name><surname>Yang</surname><given-names>S-C</given-names></name><etal/></person-group><article-title>Investigation into potent inflammation inhibitors from traditional chinese medicine</article-title><source><italic>Chemical Biology and Drug Design</italic></source><year>2011</year><volume>78</volume><issue>4</issue><fpage>679</fpage><lpage>688</lpage><pub-id pub-id-type="other">2-s2.0-80052619174</pub-id><pub-id pub-id-type="pmid">21801310</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>S-S</given-names></name><name><surname>Huang</surname><given-names>H-J</given-names></name><name><surname>Chen</surname><given-names>CY-C</given-names></name></person-group><article-title>Two birds with one stone? Possible dual-targeting H1N1 inhibitors from traditional Chinese medicine</article-title><source><italic>PLoS Computational Biology</italic></source><year>2011</year><volume>7</volume><issue>12</issue><pub-id pub-id-type="other">2-s2.0-84855282742</pub-id><pub-id pub-id-type="publisher-id">e1002315</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>HJ</given-names></name><name><surname>Jian</surname><given-names>YR</given-names></name><name><surname>Chen</surname><given-names>CYC</given-names></name></person-group><article-title>Traditional Chinese medicine application in HIV: an in silico study</article-title><source><italic>Journal of Biomolecular Structure &amp; Dynamics</italic></source><year>2014</year><volume>32</volume><issue>1</issue><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">23252879</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>K-C</given-names></name><name><surname>Chang</surname><given-names>S-S</given-names></name><name><surname>Huang</surname><given-names>H-J</given-names></name><name><surname>Lin</surname><given-names>T-L</given-names></name><name><surname>Wu</surname><given-names>Y-J</given-names></name><name><surname>Chen</surname><given-names>CY-C</given-names></name></person-group><article-title>Three-in-one agonists for PPAR-a, PPAR-<italic>&#947;</italic>, and PPAR-d from traditional Chinese medicine</article-title><source><italic>Journal of Biomolecular Structure and Dynamics</italic></source><year>2012</year><volume>30</volume><issue>6</issue><fpage>662</fpage><lpage>683</lpage><pub-id pub-id-type="other">2-s2.0-84871181814</pub-id><pub-id pub-id-type="pmid">22731403</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>KC</given-names></name><name><surname>Chang</surname><given-names>SS</given-names></name><name><surname>Tsai</surname><given-names>FJ</given-names></name><name><surname>Chen</surname><given-names>CY</given-names></name></person-group><article-title>Han ethnicity-specific type 2 diabetic treatment from traditional Chinese medicine?</article-title><source><italic>Journal of Biomolecular Structure &amp; Dynamics</italic></source><year>2013</year><volume>31</volume><issue>11</issue><fpage>1219</fpage><lpage>1235</lpage><pub-id pub-id-type="pmid">23146021</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>K-C</given-names></name><name><surname>Yu-Chian Chen</surname><given-names>C</given-names></name></person-group><article-title>Stroke prevention by traditional Chinese medicine? A genetic algorithm, support vector machine and molecular dynamics approach</article-title><source><italic>Soft Matter</italic></source><year>2011</year><volume>7</volume><issue>8</issue><fpage>4001</fpage><lpage>4008</lpage><pub-id pub-id-type="other">2-s2.0-79953746295</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>K-C</given-names></name><name><surname>Chang</surname><given-names>K-W</given-names></name><name><surname>Chen</surname><given-names>H-Y</given-names></name><name><surname>Chen</surname><given-names>CY-C</given-names></name></person-group><article-title>Traditional Chinese medicine, a solution for reducing dual stroke risk factors at once?</article-title><source><italic>Molecular BioSystems</italic></source><year>2011</year><volume>7</volume><issue>9</issue><fpage>2711</fpage><lpage>2719</lpage><pub-id pub-id-type="other">2-s2.0-80051760684</pub-id><pub-id pub-id-type="pmid">21796302</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>T-T</given-names></name><name><surname>Chen</surname><given-names>K-C</given-names></name><name><surname>Chang</surname><given-names>K-W</given-names></name><etal/></person-group><article-title>In silico pharmacology suggests ginger extracts may reduce stroke risks</article-title><source><italic>Molecular BioSystems</italic></source><year>2011</year><volume>7</volume><issue>9</issue><fpage>2702</fpage><lpage>2710</lpage><pub-id pub-id-type="other">2-s2.0-80051767195</pub-id><pub-id pub-id-type="pmid">21776525</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tou</surname><given-names>WI</given-names></name><name><surname>Chang</surname><given-names>S-S</given-names></name><name><surname>Lee</surname><given-names>C-C</given-names></name><name><surname>Chen</surname><given-names>CY-C</given-names></name></person-group><article-title>Drug design for neuropathic pain regulation from traditional Chinese medicine</article-title><source><italic>Scientific Reports</italic></source><year>2013</year><volume>3</volume><issue>article 844</issue><pub-id pub-id-type="other">2-s2.0-84880533871</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>KC</given-names></name><name><surname>Jian</surname><given-names>YR</given-names></name><name><surname>Sun</surname><given-names>MF</given-names></name><name><surname>Chang</surname><given-names>TT</given-names></name><name><surname>Lee</surname><given-names>CC</given-names></name><name><surname>Chen</surname><given-names>CY</given-names></name></person-group><article-title>Investigation of silent information regulator 1 (Sirt1) agonists from traditional Chinese medicine</article-title><source><italic>Journal of Biomolecular Structure &amp; Dynamics</italic></source><year>2013</year><volume>31</volume><issue>11</issue><fpage>1207</fpage><lpage>1218</lpage><pub-id pub-id-type="pmid">23075283</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>H-C</given-names></name><name><surname>Chen</surname><given-names>CY-C</given-names></name></person-group><article-title>Investigation of the novel lead of melanocortin 1 receptor for pigmentary disorders</article-title><source><italic>Evidence-Based Complementary and Alternative Medicine</italic></source><year>2014</year><volume>2014</volume><fpage>13 pages</fpage><pub-id pub-id-type="publisher-id">254678</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H-J</given-names></name><name><surname>Lee</surname><given-names>C-C</given-names></name><name><surname>Chen</surname><given-names>CY-C</given-names></name></person-group><article-title>Pharmacological chaperone design for reducing risk factor of Parkinson's disease from traditional chinese medicin</article-title><source><italic>Evidence-Based Complementary and Alternative Medicine</italic></source><year>2014</year><volume>2014</volume><fpage>12 pages</fpage><pub-id pub-id-type="publisher-id">830490</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Chang</surname><given-names>SS</given-names></name><name><surname>Chan</surname><given-names>YC</given-names></name><name><surname>Chen</surname><given-names>CY</given-names></name></person-group><article-title>Discovery of novel insomnia leads from screening traditional Chinese medicine database</article-title><source><italic>Journal of Biomolecular Structure &amp; Dynamics</italic></source><year>2014</year><volume>32</volume><issue>5</issue><fpage>776</fpage><lpage>791</lpage><pub-id pub-id-type="pmid">23730798</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Travins</surname><given-names>J</given-names></name><name><surname>DeLaBarre</surname><given-names>B</given-names></name><etal/></person-group><article-title>Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation</article-title><source><italic>Science</italic></source><year>2013</year><volume>340</volume><issue>6132</issue><fpage>622</fpage><lpage>626</lpage><pub-id pub-id-type="other">2-s2.0-84877620952</pub-id><pub-id pub-id-type="pmid">23558173</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CY-C</given-names></name></person-group><article-title>TCM Database@Taiwan: the world&#8217;s largest traditional Chinese medicine database for drug screening In Silico</article-title><source><italic>PLoS ONE</italic></source><year>2011</year><volume>6</volume><issue>1</issue><pub-id pub-id-type="other">2-s2.0-79251561193</pub-id><pub-id pub-id-type="publisher-id">e15939</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tou</surname><given-names>WI</given-names></name><name><surname>Chen</surname><given-names>CY</given-names></name></person-group><article-title>May disordered protein cause serious drug side effect?</article-title><source><italic>Drug Discovery Today</italic></source><year>2014</year><volume>19</volume><issue>4</issue><fpage>367</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">24184432</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CY-C</given-names></name><name><surname>Tou</surname><given-names>WI</given-names></name></person-group><article-title>How to design a drug for the disordered proteins?</article-title><source><italic>Drug Discovery Today</italic></source><year>2013</year><volume>18</volume><issue>19-20</issue><fpage>910</fpage><lpage>915</lpage><pub-id pub-id-type="other">2-s2.0-84877740191</pub-id><pub-id pub-id-type="pmid">23643489</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>B</given-names></name><name><surname>Dunbrack</surname><given-names>RL</given-names></name><name><surname>Williams</surname><given-names>RW</given-names></name><name><surname>Dunker</surname><given-names>AK</given-names></name><name><surname>Uversky</surname><given-names>VN</given-names></name></person-group><article-title>PONDR-FIT: a meta-predictor of intrinsically disordered amino acids</article-title><source><italic>Biochimica et Biophysica Acta: Proteins and Proteomics</italic></source><year>2010</year><volume>1804</volume><issue>4</issue><fpage>996</fpage><lpage>1010</lpage><pub-id pub-id-type="other">2-s2.0-76849087968</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>BR</given-names></name><name><surname>Bruccoleri</surname><given-names>RE</given-names></name><name><surname>Olafson</surname><given-names>BD</given-names></name><name><surname>States</surname><given-names>DJ</given-names></name><name><surname>Swaminathan</surname><given-names>S</given-names></name><name><surname>Karplus</surname><given-names>M</given-names></name></person-group><article-title>CHARMM: a program for macromolecular energy minimization and dynamics calculations</article-title><source><italic>Journal of Computational Chemistry</italic></source><year>1983</year><volume>4</volume><issue>2</issue><fpage>187</fpage><lpage>217</lpage></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipinski</surname><given-names>CA</given-names></name><name><surname>Lombardo</surname><given-names>F</given-names></name><name><surname>Dominy</surname><given-names>BW</given-names></name><name><surname>Feeney</surname><given-names>PJ</given-names></name></person-group><article-title>Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</article-title><source><italic>Advanced Drug Delivery Reviews</italic></source><year>2001</year><volume>46</volume><issue>1&#8211;3</issue><fpage>3</fpage><lpage>26</lpage><pub-id pub-id-type="other">2-s2.0-0035289779</pub-id><pub-id pub-id-type="pmid">11259830</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatachalam</surname><given-names>CM</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Oldfield</surname><given-names>T</given-names></name><name><surname>Waldman</surname><given-names>M</given-names></name></person-group><article-title>LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites</article-title><source><italic>Journal of Molecular Graphics and Modelling</italic></source><year>2003</year><volume>21</volume><issue>4</issue><fpage>289</fpage><lpage>307</lpage><pub-id pub-id-type="other">2-s2.0-0037212102</pub-id><pub-id pub-id-type="pmid">12479928</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hess</surname><given-names>B</given-names></name><name><surname>Kutzner</surname><given-names>C</given-names></name><name><surname>Van Der Spoel</surname><given-names>D</given-names></name><name><surname>Lindahl</surname><given-names>E</given-names></name></person-group><article-title>GRGMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation</article-title><source><italic>Journal of Chemical Theory and Computation</italic></source><year>2008</year><volume>4</volume><issue>3</issue><fpage>435</fpage><lpage>447</lpage><pub-id pub-id-type="other">2-s2.0-46249092554</pub-id><pub-id pub-id-type="pmid">26620784</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoete</surname><given-names>V</given-names></name><name><surname>Cuendet</surname><given-names>MA</given-names></name><name><surname>Grosdidier</surname><given-names>A</given-names></name><name><surname>Michielin</surname><given-names>O</given-names></name></person-group><article-title>SwissParam: a fast force field generation tool for small organic molecules</article-title><source><italic>Journal of Computational Chemistry</italic></source><year>2011</year><volume>32</volume><issue>11</issue><fpage>2359</fpage><lpage>2368</lpage><pub-id pub-id-type="other">2-s2.0-79958841703</pub-id><pub-id pub-id-type="pmid">21541964</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fletcher</surname><given-names>R</given-names></name></person-group><source><italic>Optimization</italic></source><year>1969</year><publisher-loc>London, UK</publisher-loc><publisher-name>Academic Press</publisher-name></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chovancova</surname><given-names>E</given-names></name><name><surname>Pavelka</surname><given-names>A</given-names></name><name><surname>Benes</surname><given-names>P</given-names></name><etal/></person-group><article-title>CAVER 3.0: a tool for the analysis of transport pathways in dynamic protein structures</article-title><source><italic>PLoS Computational Biology</italic></source><year>2012</year><volume>8</volume><issue>10</issue><pub-id pub-id-type="other">2-s2.0-84868156224</pub-id><pub-id pub-id-type="publisher-id">e1002708</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adelowotan</surname><given-names>O</given-names></name><name><surname>Aibinu</surname><given-names>I</given-names></name><name><surname>Adenipekun</surname><given-names>E</given-names></name><name><surname>Odugbemi</surname><given-names>T</given-names></name></person-group><article-title>The in-vitro antimicrobial activity of <italic>Abrus precatorius</italic> (L) fabaceae extract on some clinical pathogens</article-title><source><italic>The Nigerian Postgraduate Medical Journal</italic></source><year>2008</year><volume>15</volume><issue>1</issue><fpage>32</fpage><lpage>37</lpage><pub-id pub-id-type="other">2-s2.0-44949250150</pub-id><pub-id pub-id-type="pmid">18408781</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zore</surname><given-names>GB</given-names></name><name><surname>Awad</surname><given-names>V</given-names></name><name><surname>Thakre</surname><given-names>AD</given-names></name><etal/></person-group><article-title>Activity-directed-fractionation and isolation of four antibacterial compounds from <italic>Abrus precatorius</italic> L., roots</article-title><source><italic>Natural Product Research</italic></source><year>2007</year><volume>21</volume><issue>9</issue><fpage>838</fpage><lpage>845</lpage><pub-id pub-id-type="other">2-s2.0-35748929133</pub-id><pub-id pub-id-type="pmid">17763102</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shafi Sofi</surname><given-names>M</given-names></name><name><surname>Sateesh</surname><given-names>MK</given-names></name><name><surname>Bashir</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cytotoxic and pro-apoptotic effects of <italic>Abrus precatorius</italic> L. on human metastatic breast cancer cell line, MDA-MB-231</article-title><source><italic>Cytotechnology</italic></source><year>2013</year><volume>65</volume><issue>3</issue><fpage>407</fpage><lpage>417</lpage><pub-id pub-id-type="other">2-s2.0-84876465704</pub-id><pub-id pub-id-type="pmid">23081723</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>VV</given-names></name><name><surname>Sirsi</surname><given-names>M</given-names></name></person-group><article-title>Effect of <italic>Abrus precatorius</italic> L. on experimental tumors</article-title><source><italic>Cancer Research</italic></source><year>1969</year><volume>29</volume><issue>7</issue><fpage>1447</fpage><lpage>1451</lpage><pub-id pub-id-type="other">2-s2.0-0014544475</pub-id><pub-id pub-id-type="pmid">5799161</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Disordered disposition predicted by PONDR-Fit.</p></caption><graphic xlink:href="BMRI2014-364625.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Binding site of IDH2 R140Q mutant protein defined as the volume of AGI-6780 and root-mean-square deviation value between crystallized structure (orange) and docking pose (violet) of AGI-6780.</p></caption><graphic xlink:href="BMRI2014-364625.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Chemical scaffold of controls and top two TCM candidates with their scoring function and sources.</p></caption><graphic xlink:href="BMRI2014-364625.003"/></fig><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Docking pose of IDH2 R140Q mutant protein complexes with (a) AGI-6780, (b) precatorine, and (c) abrine.</p></caption><graphic xlink:href="BMRI2014-364625.004"/></fig><fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Root-mean-square deviations in units of nm for protein and ligand over 5000&#8201;ps of MD simulation for IDH2 R140Q mutant proteins and protein complexes with AGI-6780, precatorine, and abrine.</p></caption><graphic xlink:href="BMRI2014-364625.005"/></fig><fig id="fig6" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Radii of gyration for protein over 5000&#8201;ps of MD simulation for IDH2 R140Q mutant proteins and protein complexes with AGI-6780, precatorine, and abrine.</p></caption><graphic xlink:href="BMRI2014-364625.006"/></fig><fig id="fig7" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Variation of total energy for complex over 5000&#8201;ps of MD simulation for IDH2 R140Q mutant proteins and protein complexes with AGI-6780, precatorine, and abrine.</p></caption><graphic xlink:href="BMRI2014-364625.007"/></fig><fig id="fig8" orientation="portrait" position="float"><label>Figure 8</label><caption><p>Variation of (a) total solvent accessible surface area, (b) hydrophobic surface area, and (c) hydrophilic surface area over 5000&#8201;ps of MD simulation for IDH2 R140Q mutant proteins and protein complexes with AGI-6780, precatorine, and abrine.</p></caption><graphic xlink:href="BMRI2014-364625.008"/></fig><fig id="fig9" orientation="portrait" position="float"><label>Figure 9</label><caption><p>Mean square displacement (MSD) for (a) protein and (b) ligand over 5000&#8201;ps of MD simulation for IDH2 R140Q mutant proteins and protein complexes with AGI-6780, precatorine, and abrine.</p></caption><graphic xlink:href="BMRI2014-364625.009"/></fig><fig id="fig10" orientation="portrait" position="float"><label>Figure 10</label><caption><p>Root-mean-square fluctuation (RMSF) for residues in (a) chain A and (b) chain B of IDH2 R140Q mutant proteins and protein complexes with AGI-6780, precatorine, and abrine.</p></caption><graphic xlink:href="BMRI2014-364625.010"/></fig><fig id="fig11" orientation="portrait" position="float"><label>Figure 11</label><caption><p>Root-mean-square deviation value (upper left half) and graphical depiction of the clusters with cutoff 0.105&#8201;nm (lower right half) for IDH2 R140Q mutant proteins and protein complexes with AGI-6780, precatorine, and abrine.</p></caption><graphic xlink:href="BMRI2014-364625.011"/></fig><fig id="fig12" orientation="portrait" position="float"><label>Figure 12</label><caption><p>Docking poses of middle RMSD structure in the major cluster for IDH2 R140Q mutant protein complexes with AGI-6780, precatorine, and abrine.</p></caption><graphic xlink:href="BMRI2014-364625.012"/></fig><fig id="fig13" orientation="portrait" position="float"><label>Figure 13</label><caption><p>Analysis of transport pathways for IDH2 R140Q mutant protein complexes with (a) AGI-6780, (b) precatorine, and (c) abrine.</p></caption><graphic xlink:href="BMRI2014-364625.013"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>H-bond occupancy for key residues of IDH2 R140Q mutant protein with AGI-6780 and top TCM compounds overall 5000&#8201;ps of molecular dynamics simulation.</p></caption><table-wrap-foot><fn><p>H-bond occupancy cutoff: 0.3&#8201;nm.</p></fn></table-wrap-foot></table-wrap></floats-group></article>